Affinity completes cGMP plant expansion

Related tags Pharmacology

US CMO Affinity Life Sciences has completed the expansion of its manufacturing plant, adding capacity for cGMP lyophilisation and biomarker development.

The facility, in Milford, New Hampshire, is a key part of the contract manufacturing organisation’s (CMO) effort to build its position in the rapidly expanding assay development sector according to company president Tod Gavron.

With the additional space, we will improve our overall production and provide greater flexibility with regards to project scheduling and scope. We are also pleased to provide on-site lyophilization services​.”

Demand for biomarkers has increased markedly in recent years as the drug industry has sought to improve the efficacy of clinical development by reducing attrition rates and, more recently, to develop companion diagnostics.

Industry need for lyophilisation is also set to expand as, increasingly, innovative pharmaceutical companies focus on the production of biologic drugs that require this type of processing.

Related topics Contract Manufacturing & Logistics

Related news